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Abstract
Background: Retinal optical coherence tomography (OCT) is a clinical and research tool in multiple sclerosis, where
it has shown significant retinal nerve fiber (RNFL) and ganglion cell (RGC) layer thinning, while postmortem studies
have reported RGC loss. Although retinal pathology in experimental autoimmune encephalomyelitis (EAE) has been
described, comparative OCT studies among EAE models are scarce. Furthermore, the best practices for the
implementation of OCT in the EAE lab, especially with afoveate animals like rodents, remain undefined. We aimed
to describe the dynamics of retinal injury in different mouse EAE models and outline the optimal experimental
conditions, scan protocols, and analysis methods, comparing these to histology to confirm the pathological
underpinnings.
Methods: Using spectral-domain OCT, we analyzed the test-retest and the inter-rater reliability of volume,
peripapillary, and combined horizontal and vertical line scans. We then monitored the thickness of the retinal layers
in different EAE models: in wild-type (WT) C57Bl/6J mice immunized with myelin oligodendrocyte glycoprotein
peptide (MOG35–55) or with bovine myelin basic protein (MBP), in TCR
2D2 mice immunized with MOG35–55, and in
SJL/J mice immunized with myelin proteolipid lipoprotein (PLP139–151). Strain-matched control mice were sham-
immunized. RGC density was counted on retinal flatmounts at the end of each experiment.
Results: Volume scans centered on the optic disc showed the best reliability. Retinal changes during EAE were
localized in the inner retinal layers (IRLs, the combination of the RNFL and the ganglion cell plus the inner
plexiform layers). In WT, MOG35–55 EAE, progressive thinning of IRL started rapidly after EAE onset, with 1/3 of total
loss occurring during the initial 2 months. IRL thinning was associated with the degree of RGC loss and the severity
of EAE. Sham-immunized SJL/J mice showed progressive IRL atrophy, which was accentuated in PLP-immunized
mice. MOG35–55-immunized TCR
2D2 mice showed severe EAE and retinal thinning. MBP immunization led to very
mild disease without significant retinopathy.
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Conclusions: Retinal neuroaxonal damage develops quickly during EAE. Changes in retinal thickness mirror
neuronal loss and clinical severity. Monitoring of the IRL thickness after immunization against MOG35–55 in C57Bl/6J
mice seems the most convenient model to study retinal neurodegeneration in EAE.
Keywords: Experimental autoimmune encephalomyelitis, Experimental optic neuritis, Optical coherence
tomography, Optokinetic response, Multiple sclerosis, Neurodegeneration,
Introduction
Optic neuritis (ON) is an acute, inflammatory demyelin-
ating disease of the optic nerve resulting in impairment
of vision. Fifty percent of patients with multiple sclerosis
(MS) experience ON during the course of the disease. In
up to 20% of them, ON is the presenting feature of MS
[1]. Optical coherence tomography (OCT) allows for
non-invasive, reproducible imaging of the live retina and
its non-myelinated axons, and serves as a potential bio-
marker for estimating the neuroaxonal loss in the central
nervous system (CNS).
While no animal model can fully recapitulate all
pathophysiological aspects involved in MS, some models
have proven useful for shedding light on the pathogenic
mechanisms underlying neuroinflammatory injury, as
well as to test candidate therapeutics. The most com-
monly studied animal model of MS is murine experi-
mental autoimmune encephalomyelitis (EAE), where
mice develop varying degrees of optic neuritis, white
matter injury, and ascending myelitis [2].
After immunization of SJL/J mice with PLP139–151,
Shindler et al. detected loss of retinal ganglion cells
(RGCs, the neurons whose axons form the optic nerve)
at day 14, starting with a 43% reduction which increased
to 50% by day 18. RGC loss was correlated with the se-
verity of inflammation, suggesting that RGC loss in EAE
is a direct consequence of optic neuritis [3]. In C57B1/6
mice, active immunization with myelin oligodendrocyte
glycoprotein peptide (MOG35–55) or adoptive transfer of
MOG-specific T cells causes severe optic neuritis [4].
Because MOG expression is higher in the optic nerves
than in the spinal cord, even suboptimal doses of MOG
can induce experimental optic neuritis in the absence of
clinically evident paraparesis in EAE [5]. The TCR2D2
mouse line has a MOG-specific T cell receptor leading
to severe clinical disability of immunized animals. While
TCR2D2 mice can develop spontaneous ON more fre-
quently than they develop spontaneous EAE, the use of
pertussis toxin (PT) promotes higher, timely incidence
of ON and EAE [6]. In this context, Guan et al. found
that RGC loss occurred progressively, reaching 39% at
day 16 after injection with PT [6]. Horstmann and col-
leagues studied the retinas and optic nerves of C57B1/6
mice 23 days after the induction of MOG35–55 EAE [7].
In this study, the severity of cellular infiltration and
demyelination of the optic nerve as assessed by chemical
staining techniques (such as hematoxylin-eosin and luxol
fast blue staining, respectively) correlated with the clin-
ical EAE score. In this setting, EAE led to an 18% loss of
RGC although no change in thickness of any retinal
layer could be identified by measuring retinal sections
under the microscope likely because of artifacts induced
by fixation and tissue preparation.
Although these in vivo models of experimental ON
have proven potentially useful to study mechanisms of
neurodegeneration and neuronal survival with an auto-
immune reaction mediated by stimulating an adaptive
immune response, they are mainly focused upon histo-
logical measures (either by staining or by retrograde
labeling of RGC). Most of these studies had short obser-
vational periods of 21 to 40 days after immunization and
lacked longitudinal assessments for time tracking of cell
injury and loss. Neurodegeneration, however, is a dy-
namic process. In recent years, the development of non-
invasive, retinal imaging techniques for animal models,
such as OCT, has helped shed light on the longitudinal
neurodegenerative changes during neuroinflammation.
This approach has, additionally, emerged as a platform
for the preclinical screening of candidate neuroprotec-
tive compounds in MS and other neuroinflammatory
diseases [8–10].
Studies comparing anterior visual pathway pathology
and in vivo imaging characteristics of different EAE
models are lacking. A detailed characterization of retinal
injury in animals is essential as it can facilitate transla-
tional research employing experimental designs that are
directly adaptable to human clinical trials. To date, the
most appropriate animal model to study ON in EAE has
not been defined. The utilization of spectral-domain
(SD) OCT in animal models has been constrained by
technical and optical issues. To date, although different
segmentation algorithms have been tested in volume
scans [11], it is not apparent which OCT scanning
protocol is most suitable to assess thickness changes of
the retinal layers. Acceptable reproducibility and reliabil-
ity have been reported using a custom-made algorithm
for automated segmentation of retinal layers in retinal
volume scans from mice [12]. However, in 2D scans, the
automatic segmentation of the different retinal layers in
mice is often prone to errors. Thus, segmentation of
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retinal layers is conducted manually or semi-automatically
with manual correction, a laborious task that can poten-
tially introduce systematic errors (e.g., due to examiner
subjectivity and fatigue bias). It is, therefore, crucial to as-
sess the reproducibility of consecutive assessments and
the inter-rater reliability to identify scan protocols associ-
ated with high validity and reliability.
This work aimed to describe the dynamics of retinal
injury after acute ON in different mouse models of EAE
and to define the optimal mouse model, experimental
conditions, and analysis methods for the assessment of




As a first step, we investigated which OCT scanning
protocols are associated with the best test-retest reliabil-
ity for retinal layer measurements. We then ran a series
of experiments aimed at determining the optimal dur-
ation and the ideal mouse model for studying retinal
changes in EAE. We analyzed the dynamics of retinal in-
jury after direct immunization against MOG35–55 and
MBP in C57BL/6J mice, MOG35–55 EAE in TCR
2D2
transgenic mice, and PLP139–151 in SJL/J mice. We ana-
lyzed changes in retinal thickness as assessed by serial
retinal OCT, using sham-immunized, age-matched fe-
male mice from the same strain and/or WT littermates
for TCR2D2 transgenic mice as controls for each model.
Mice
We bred C57Bl/6J and TCR2D2 transgenic mice from
parents purchased from the Jackson Laboratories (Bar
Harbor, ME, USA). SJL/J mice were provided by S. S.
Zamvil, University of California, San Francisco. We per-
formed our experiments on female and male (for
TCR2D2) 8- to 10-week-old mice.
Anesthesia
Before imaging, mice were anesthetized by mask inhal-
ation of isoflurane vaporized at concentrations of 1.5%
(2 l/min) and their pupils were dilated with 1% tropica-
mide ophthalmic solution (Akorn, Lake Forest, IL).
Compared to the use of intraperitoneal (i.p.) injection
of ketamine and xylazine, this approach has proved to
be simpler and safer, allowing for rapid induction and
easy control of the depth of anesthesia, with a low
percentage of complications [13]. Furthermore, this
method avoids the xylazine-induced acute, reversible
cataract in rodents [14].
Optical coherence tomography
We performed retinal imaging using Spectralis™ OCT
(Heidelberg Engineering, Heidelberg, Germany). During
the exams, mice were placed on a custom-made mouse
restrainer allowing free rotation and alignment of the
eye to ensure the retinal laser was properly centered on
the optic nerve head [15]. SD-OCT imaging was per-
formed with and without the help of the TruTrack™ eye
tracker that uses the fundus image to achieve imaging,
maintaining registration of the image to enhance fidelity
brought with averaging and to reduce breathing artifacts.
We adapted for the optical properties of the mouse eye
by using a custom contact lens during the examination,
along with hydroxypropyl methylcellulose 0.3% (Gen-
Teal™ ophthalmic gel, Novartis, Basel, Switzerland) to
keep the eye moist and to ensure refraction continuity.
Furthermore, we altered the Spectralis™ hardware by
adding a 78-diopter lens in front of the camera and by
adjusting the length of the reference arm (an option of
the Spectralis software). All scans were acquired with an
initial focus distance of 42D followed by manual correc-
tion. For volume scans, retinal layer thicknesses were
calculated using the ETDRS grid with diameters of 1, 2,
and 3 mm centered on the optic disc. We calculated the
thickness of each retinal layer by averaging each sector
of the grid, excluding the center which corresponded to
the optic nerve head. Each volume scan consisted of 49
B-Scans recorded in high-resolution mode at 100 ART
(rasterized from 100 averaged A-scans). The current ver-
sion of the software does not allow for the exclusion of
the center in horizontal and vertical line scans, which we
combined into a crossline by averaging individual hori-
zontal and vertical layer thicknesses. We corrected seg-
mentation artifacts at the disc by drawing straight lines
between its opposing borders (Fig. 1). For each experi-
ment, OCT imaging was performed at the time points
indicated in the “Results” section.
Investigation of the test-retest and inter-rater reliability
for retinal layer assessments
We performed volume, peripapillary ring, and horizontal
and vertical line scans to analyze the thickness of each
retinal layer in 10 C57BL/6J mice obtained from Jackson
Laboratories (Bar Harbor, ME, USA). We assessed the
repeatability of OCT acquisition by removing and re-
placing the subject mouse onto the mount after each
completed scan program, repeating the imaging with
and without the Spectralis follow-up function—which
utilizes the Spectralis eye tracking function to register
images during follow-up scans. We assessed the quality
scores (a measure of signal intensity) for each protocol
and considered them acceptable if above 20 and excel-
lent if above 30. Using automated segmentation by the
Heidelberg Eye ExplorerTM software (version 1.7.1.0
with the 5.10 beta version of the segmentation algo-
rithm) and subsequent manual correction of segmenta-
tion errors, we obtained the thickness of the retinal
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layers on each scan. Two independent investigators de-
termined the segmented thicknesses of each OCT scan.
We assessed the total retinal thickness, individual ret-
inal layers, and inner retinal layers (IRLs), defined as
the combination of the retinal nerve fiber layer
(RNFL) and the ganglion cell and the inner plexiform
layer (GCIPL) [16].
Optokinetic response
The optokinetic response was assessed as a measure for
the visual acuity with a testing chamber and the Opto-
Motry™ software from CerebralMechanics™ (Lethbridge,
Canada). A detailed description of the device [17] and
methodology [8] is given elsewhere. In brief, we posi-
tioned the mice on a platform surrounded by TFT moni-
tors displaying a virtual cylinder of black gratings (100%
contrast) rotating in varying directions and at different
frequencies. The mice head movements tracking the
grating were evaluated by an investigator blinded for the
experimental groups. The spatial threshold frequency at
which tracking was no longer possible was determined
as a measure of visual function.
Induction and clinical scoring of EAE
Direct immunization against MOG35–55 in C57Bl/6J and
TCR2D2 mice
Animals were immunized subcutaneously with 100 μg of
MOG35–55 peptide (Genemed Synthesis, San Antonio,
TX, USA) in complete Freund’s adjuvant (CFA) contain-
ing 400 μg Mycobacterium tuberculosis (Mt) H37Ra
(Difco Laboratories, Detroit, MI, USA). Mice received
200 ng PT (List Biological, Campbell, CA, USA) by i.p.
Fig. 1 a–c Fundus image of mouse retina with segmentation of OCT, where each green line depicts a B-scan. a Volume scan taken from raster
scan of the optic nerve head. Area in blue includes the region of calculated volume. b Peripapillary ring and c horizontal and vertical line scans.
d–f Examples of B-scans obtained from volume (d), peripapillary ring (e), and (f) line scans. On the right half of each B-scan, the results of the
semi-automated segmentation of the layers are shown with retinal layers labeled. g Horizontal B-scan in a SJL/J mouse, with atrophy of outer
retinal layers, a characteristic finding in retinal degeneration 1. h Schematic representation of a retina dissected from an eyeball (left) and a whole
mount for histological analysis (right). The dotted line represents cuts made on the retina; the red squares represent areas analyzed in the central
(1), mid-peripheral (2), and far-peripheral retina (3)
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injection at the time of and 48 h post-immunization.
Control mice were sham-immunized with phosphate-
buffered saline in CFA and received the same PT
dosage.
Direct immunization against PLP139–151 in SJL/J mice
SJL/J mice were injected with 100 μg PLP139–151 in
400 μg CFA subcutaneous and 2 × 50 ng PT i.p. on days
0 and 2. Control mice were sham-immunized with phos-
phate buffer saline in CFA and received the same PT
dosage.
Direct immunization against MBP in C57Bl/6J mice
Animals were immunized with 400 μg of bovine MBP
(Sigma, Darmstadt, Germany), emulsified in 200 μl of
CFA, and supplemented with 4 mg of Mt H37Ra, both
purchased from Difco. Additionally, mice received i.p.
injections of 200 ng of PT (Sigma-Aldrich, Darmstadt,
Germany) on days 0 and 2 after immunization. We re-
corded daily clinical scores, as detailed in Table 1.
Post-acquisition analysis
Using automated segmentation by the Heidelberg Eye
Explorer™ software (version 1.7.1.0 with the 5.10 beta
version of the segmentation algorithm) and subsequent
manual correction of segmentation errors, we obtained
the thickness of the retinal layers on each scan. For vol-
ume scans, retinal layer thicknesses were calculated
using the early treatment of diabetic retinopathy
(ETDRS) study grid (1, 2, 3 mm) centered on the optic
disc (Fig. 1). We calculated the thickness of each retinal
layer by averaging each sector of the grid, excluding the
center which corresponded to the optic nerve head. In
line scans, we corrected segmentation artifacts at the
disc by drawing straight lines between the opposing bor-
ders of the optic disc. We determined the thickness of
individual retinal layers and the IRL [16]. Thickness data
were exported from the segmentation software onto an
Excel spreadsheet (Microsoft, WA, USA). In the case of
SJL/J mice, which are homozygous for the allele Pde6brd1
(retinal degeneration 1), we used an 8 × 8 grid, obtaining
retinal thickness values only in those sectors where im-
aging of the inner retinal layers was feasible (Fig. 1d).
Histological analysis and immunofluorescence microscopy
Mice were sacrificed with an overdose of isoflurane. Car-
diac perfusion was performed, and optic nerves and ret-
inae were dissected. Optic nerves were fixated in 4%
paraformaldehyde (PFA) overnight and dehydrated in su-
crose solutions with increasing concentrations. After em-
bedding in OCT compound (Sakura™ Finetek),
longitudinal sections of 5 μm were cut for immunohistolo-
gical analysis. The antibodies used for immunofluores-
cence microscopy are listed in Table 2. To examine
adaptive immune infiltration by CD3+ lymphocytes and
innate immune activation—microglial/macrophage infil-
tration—as well as the myelin status of the optic nerves,
slices were incubated with CD3 (1:400, Dako), Iba1 (1:500,
Wako chemicals), and MBP (1:500, Millipore) antibodies,
respectively. For a further rating of immune cell infiltra-
tion in optic nerves, hematoxylin and eosin (HE) staining
was performed. RGC count was calculated by a semi-
automated count of βIII-tubulin- or Brn3a-positive cells
on retinal flatmounts. Briefly, retinae were stained with
Brn3a (1:200, Santa Cruz Biotechnology, cat # sc-31984)
or βIII-tubulin antibody (1:1000, Biolegend) and flat-
mounted on glass slides. Each retina was then divided into
four quadrants (three areas per quadrant: central, mid-
Table 1 EAE clinical severity scores
0 No signs of disease.
0.5 Mild tail paresis: tip of the tail is weak and/or mouse does not spin tail.
1 Obvious tail paresis or plegia.
1.5 When flipped on its back, the mouse does not turn instantly in > 50% of the cases (this score can only be assigned when signs of tail weakness
as described in 0.5 and 1 are present at the same time).
2 Mild signs of hind limb paresis, like abnormal or slow gait, abnormal posture of the posterior part of the body.
2.5 Obvious signs of hind limb paresis, like abnormal, slow, and weak movements of one or both hind limbs.
3 Signs of hind limb plegia: drags one hind limb behind (if the limb is moved a little but it does not help the mouse to move, this will count as a
3).
3.5 Signs of hind limb plegia: drags both hind limbs behind (if the limbs are moved a little but it does not help the mouse to move, this will count
as a 3.5).
4 Mild signs of quadriparesis (weakness of all 4 limbs), as described in 2–3.5 and signs of weakness of one or both front limbs, like reduced speed
when pulling itself forward, inability to push its chest up from ground, or reduced ability (shorter duration) to hold itself up against gravity on
the edge of the cage.
4.5 Quadriplegia: cannot or barely pull itself forward or hold itself on the edge of the cage (in this stage the mouse has to be monitored closely
and has to be sacrificed before 24 h if the condition does not improve).
5 Mouse found dead.
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periphery, and far-periphery) (Fig. 1e). For each eye,
Brn3a+ or βIII-tubulin+ cell count was summed up from
all 12 areas imaged as previously described [18].
Electron microscopy
For transmission electron microscopy (TEM), mice were
sacrificed and cardiac perfusion was performed with 2%
PFA and 2.5% glutaraldehyde (GA). Optic nerves were
dissected and incubated in the fixative containing 2%
PFA and 2.5% GA at 4 °C for 3 h, followed by incubation
in 1% osmium tetroxide for 2 h. Dehydration was
achieved using acetone at increasing concentrations, and
block contrast was applied (1% phosphotungstic acid/
0.5% uranylacetate in 70% acetone). A Spurr embedding
kit (Serva, Heidelberg, Germany) was used according to
the manufacturer’s protocol. Ultrathin sections of 70 nm
were cut using an Ultracut EM UC7 (Leica) and stained
with lead-citrate [19] and 1.5% uranyl-acetate. Images
were captured at various magnifications using a TEM
H7100/100KV (Hitachi, Tokyo, Japan) using a Moroda
SIS Camera system and were subsequently processed by
Olympus ITEM 5.0 Software.
Statistical analysis
We performed the statistical analysis with SPSS version
22 (IBM). Data are presented as mean ± standard error
of the mean (SEM). We calculated the area under the
curve of EAE daily scores for each group. For all OCT
scans, we calculated the two-way mixed effect absolute
agreement interclass correlation coefficient (ICC) to as-
sess the reliability of the measurements of every layer
obtained by the two independent raters (“inter-rater reli-
ability”) and to assess the repeatability of consecutive
scans (“test-retest reliability”). We report the ICC and
the 95% confidence intervals (CI). ICC values above 0.9
were considered as excellent, between 0.8 and 0.9 as
good, between 0.7 and 0.8 as acceptable, between 0.6
and 0.7 questionable, between 0.5 and 0.6 as poor, and
below 0.5 as unacceptable [20]. Differences in retinal
thickness were analyzed using generalized estimating
equations (GEE) with an exchangeable correlation
matrix to adjust for intrasubject inter-eye correlations.
We studied the association of OCT results with EAE se-
verity and RGC loss by GEE association analyses, to
identify which measurements could be used as surro-
gates for neuronal injury. Differences in RGC survival
were analyzed with a one-way ANOVA and Holm-Sidak
post hoc test. P values are designated as follows: *P ≤
0.05, **P ≤ 0.01, and ***P ≤ 0.001. For calculation of the
sample sizes required for neuroprotection studies, we
performed a power analysis using G*Power (Version
3.1.9.2) for an α of 0.05 and a power (1-ß) of 0.8.
Results
The OCT quality scores were good for the ring and ex-
cellent for cross and volume scans (Additional file 1: Fig-
ure S1).
Inter-rater reliability
Semi-automated segmentation of the IRL was feasible
for all retinal layers in all three scanning protocols
(Fig. 1). Volume scans provided excellent inter-rater reli-
ability with ICC values of above 0.9 for all assessments
(Additional file 2: Figure S2). Cross scans (average of
horizontal and vertical line scans) and peripapillary ring
scans provided a good to excellent inter-rater reliability
for the assessment of the IRL thickness (ICC 0.961, 95%
CI 0.913–0.983, and ICC 0.816, 95% CI 0.468–0.932, re-
spectively) while the RNFL showed good reliability for
cross scans and unacceptable reliability for ring scans
(ICC 0.828, 95% CI 0.533–0.930, and ICC 0.278, 95% CI
− 0.244–0.666, respectively).
Test-retest reliability
We obtained the highest reproducibility with volume
scans, which showed excellent reliability for the assess-
ment of the IRL and the GCIPL (Additional file 3: Figure
S3). Cross and peripapillary scans provided excellent
Table 2 List of antibodies used for immunofluorescence microscopy
Type Manufacturer Catalog # Host species Dilution used
Primary antibodies Anti-CD3 Dako, Hamburg, Germany A0452 Mouse 1:400
Anti-Iba1 Wako, Richmond, VA, USA 019-19741 Rabbit 1:500
Anti-MBP Millipore, Burlington, MA, USA MAB386 Rat 1:500
Anti-Brn3a Santa Cruz Biotechnology, Dallas, TX, USA sc-31984 Goat 1:200
Anti-βIII-tubulin Biolegend, San Diego, CA, USA 801201 Mouse 1:1000
Seconday antibodies Alexa Fluor-555 Anti-Goat Life Technologies, Carlsbad, CA, USA A-21432 Donkey 1:200
Alexa Fluor-488 Anti-Rabbit Life Technologies, Carlsbad, CA, USA A-21206 Donkey 1:200
Cy3 anti-Rabbit Millipore, Burlington, MA, USA AP187c Goat 1:500
Cy3 anti-Mouse Millipore, Burlington, MA, USA AP124c Goat 1:500
Cy3 anti-Rat Millipore, Burlington, MA, USA AP183C Goat 1:500
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reproducibility only for the measurement of IRL thick-
ness (0.918 [95% CI 0.492–0.983] and 0.950 [95% CI
0.508–0.993]) and, in the case of cross scans, also for the
GCIPL (0.937 [95% CI 0.746–0.985]) while the RNFL
showed a poor reliability for cross scans and a question-
able reliability for ring scans (0.551 [95% CI − 0.568–
0.89] and 0.624 [95% CI − 0.655–0.937]). The follow-up
function did not add significantly to reproducibility.
In summary, in vivo retinal imaging by OCT was asso-
ciated for a high inter-rater and test-retest reliability for
the IRL and can, therefore, be used for the in vivo moni-
toring of neuroaxonal loss, e.g., in the context of optic
neuritis.
A summary of the longitudinal experiments performed
in EAE and their results is outlined in Table 3.
Retinal changes during 120 days after immunization with
MOG35–55 or MBP in WT C57Bl/6J and with MOG35–55 in
TCR2D2 mice
IRL swelling was evident 2 weeks after immunization of
WT mice with MOG35–55, which corresponded to clin-
ical EAE, and was followed by progressive thinning and
loss of RGC.
After MOG35–55 immunization, TCR
2D2 mice devel-
oped a severe clinical disability. Those suffering from
quadriparesis had to be fed with liquid gel and soaked
chow. Some animals (n = 2), that received sham
immunization (PT and CFA), developed spontaneous
clinical signs. Although C57BL/6 mice are often consid-
ered resistant to EAE induced by MBP, some data sug-
gest otherwise [21, 22]. Thus, we studied the disease
course and phenotype of retinal injury in this model as
well. Clinical signs were minimal and started around the
same day as MOG35–55-induced EAE (Fig. 2).
Contrary to our observations in WT C57Bl/6J mice
immunized with MOG35–55, IRL thinning was already
evident after 2 weeks in TCR2D2 mice. However, after 60
days, no differences were observed between WT C57Bl/
6J and TCR2D2 mice anymore, mainly because TCR2D2
animals (~ 30%) were sacrificed due to development of
severe clinical EAE, reducing the number of animals
with strong IRL degeneration. Mean IRL of the sham
TCR2D2 group showed no thickness increase after a
period of 120 days, while healthy WT controls gained up
to 4 μm compared to the baseline measurement, suggest-
ing that ON neurodegeneration occurs in TCR2D2 mice
also in the absence of clinical EAE signs (Fig. 2b). As
IRL thickness in control mice was subject to dynamic
changes, we also analyzed the difference between EAE
mice and the average thickness of healthy control mice,
at each time point after immunization. This allowed for
better visualization of the pace and extent of retinal at-
rophy after demyelinating injury in EAE mice. In line
with the clinical disability of MBP-immunized mice,
neither degeneration of the IRL (Fig. 2c) nor the total
retina (data not shown) was detected by OCT analysis
and no significant reduction of retinal ganglion cells
(RGC) (Fig. 2d, e) was observed at 120 days after MBP
immunization compared to the sham control. Staining
of the RGC from sham TCR2D2 mice confirmed the data
of the OCT measurements, showing a reduced number
of βIII-tubulin-positive cells in the retinae, also in those
with no limb paresis. MOG-immunized TCR2D2 mice
showed strong RGC reduction but also high variances
between the single individuals (Fig. 2d, e).
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Fig. 2 a Clinical EAE score of C57Bl/6J mice immunized with MOG or MBP peptide, as well as TCR2D2 transgenic mice immunized with MOG
peptide. b Change of the inner retinal layers of TCRWT and TCR2D2 mice. c IRL change of C57BL/6J mice immunized with MBP. d Retinal
wholemounts stained by βIII-tubulin antibody from groups indicated in a. The representative images display the most severe disease progression.
e The bar graph shows the RGC density 120 days after immunization. Time courses and bar graphs represent the pooled mean ± SEM of two
separate EAE experiments each with at least four animals per group, *P > 0.05; **P < 0.01; ***P < 0.001; time courses (area under the curve) were
compared to sham, and bar graph compared to sham TCRWT mice by ANOVA with Dunnett’s post hoc test
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HE-stained optic nerves from sham-immunized
TCR2D2 mice showed immune cell infiltration, com-
pared to sham WT littermates, demonstrating the pres-
ence of ON, also in animals with no clinical signs.
TCR2D2 mice immunized with MOG35–55 had severe
inflammatory infiltration, exceeding the ON score of
the WT control. Staining of the optic nerve revealed no
significant cumulative infiltration of immune cells after
MBP immunization, suggesting a mild disease path-
ology (Fig. 3).
Increased T cell infiltration, microglial activation, and
demyelination of the optic nerve were observed 120 days
after immunization of WT mice with MOG35–55 peptide.
Microglia activation, as well as T cell infiltration, was
even present in TCR2D2 mice after sham immunization
with CFA and PT. Even more severe infiltration of CD3-
positive T cells into the optic nerve and myelin degrad-
ation was observed in TCR2D2 EAE mice compared to
WT animals, while microglial activation was similar
(Fig. 3). Despite no significant changes in cellular infil-
trates assessed by HE staining, we observed an increased
infiltration of CD3-stained T cells at day 120 in optic
nerves of MBP-immunized mice, while microglia activa-
tion and demyelination was unaltered.
To determine the effects of EAE on the ultrastructure
of the myelin sheath, we performed electron microscopy
of ultrathin cross sections of the optic nerve from sham-
and MOG35–55-immunized C57Bl/6J mice. Macroscopic
analyses of the optic nerves revealed a normal myelin
sheath in the sham-immunized group while optic nerves
of EAE mice displayed a prominent decrease of myelin-
ated axons and destruction of the myelin structure
(Fig. 4a). A quantitative analysis of the myelin structure
revealed a significantly lower myelin-axon ratio in
MOG- compared to sham-immunized mice confirming
the impression of myelin damage in MOG EAE from
our macroscopic investigations (Fig. 4b).
In summary, immunization of C5Bl/6J mice with
MOG35–55 peptide but not MBP induced robust
EAEON, detectable by ON histology and leading to a de-
generation of the IRL and RGCs detectable by OCT and
histology, respectively. This was even more pronounced
and often leading to death in TCR2D2 mice, which also
displayed mild symptoms of ON when sham-immunized
despite no motor symptoms.
Chronic retinal changes during 9months after
immunization and visual testing in MOG EAE in WT
C57Bl/6J mice
In the eyes of control animals, we observed a progressive
thickening of the retinae mirroring weight gain most
likely corresponding to the natural growth of the eyes of
the 6–8-week-old mice (Fig. 5a). In EAE eyes, progres-
sive thinning of the IRL started rapidly after the disease
onset, with 1/3 of total loss occurring during the initial
2 months (− 4.25 ± 0.87 μm compared to controls, P <
0.001 at month 2; − 13.39 ± 1.33 μm, P < 0.001 at month
9). Inner nuclear layer (INL) thinning was detectable
from the second month after immunization in EAE mice
while INL thickness remained constant throughout the
experiment in control mice.
As we identified the WT C57Bl/6J mice as a very suit-
able model for studying retinal injury in EAE, we chose
to investigate the functional outcome of the structural
results. Visual function was assessed by the optokinetic
response of the mice, using the spatial frequency thresh-
old as a readout for visual acuity. It was significantly re-
duced in EAE mice with values of 0.23 cycles per degree
(c/d) compared to 0.33 c/d for sham-EAE control mice
after 120 days of EAE (Fig. 5c).
After 9 months, the RGC density halved (4665.83 ±
360 total Brn3a cells counted per eye versus 10,206.78 ±
265, P < 0.001) in immunized mice. This finding was
consistent along all three retinal sectors (central, mid-
peripheral, and far peripheral) (Fig. 5d).
Investigating the IRL thickness at each time point (1,
2, 5, 7, and 9 months after immunization), we analyzed
its association with the final RGC count (obtained at the
end of the experiments, 9 months after immunization)
and the total EAE score area under the curve (an indica-
tor of the overall clinical severity and burden of disease)
(Fig. 5e). IRL thinning during EAE was significantly asso-
ciated with RGC loss (ß GEE association coefficient
317.4, 95% CI 241.1, 393.7, P < 0.0001 at month 9 after
immunization) and disease severity (ß − 0.02, 95% CI −
0.03, − 0.001, P = 0.031 at month 9).
Chronic retinal changes during 7months after
immunization in PLP139–151 EAE in SJL/J mice
We sought to characterize the dynamic changes in ret-
inal thickness in SJL/J mice following immunization
against PLP139–151. In this mouse strain, not only immu-
nized mice but also sham-injected controls showed pro-
gressive IRL atrophy, due to the retinal degeneration
linked to the homozygous mutation of the Pde6brd1
gene. However, in PLP-immunized mice, the IRL thin-
ning was significantly aggravated after the second month
following immunization (Fig. 6).
We concluded that the retinal degeneration also oc-
curring in sham-injected controls makes the SJL mouse
strain suboptimal for studies investigating the effects of
optic neuritis.
Power analysis for neuroprotection studies
The results outlined above suggested that MOG35–55
EAE in C57Bl/6J model is particularly well suited for the
investigation of therapeutic strategies aiming at prevent-
ing neuroaxonal loss. In this context, it is important to
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know the number of mice necessary to detect efficacy
for given effect size. To this end, we used data from a
dataset from our recently published work on the protect-
ive effects of alpha-lipoic acid in EAE (Dietrich et al. [8],
J Neuroinflammation) comparing the results of the dif-
ferent structural and functional readouts in a power ana-
lysis. For OCT measurements at the endpoint 120 days
after immunization, we determined a minimum sample
size of 14 animals per group to detect the 20% difference
in IRL thickness change observed at an effect strength of
1.1, considering that the mean of the inner retinal layers
changed by 1.7 μm in vehicle-treated mice and was asso-
ciated with a standard deviation of 1.52 μm. By perform-
ing several longitudinal measurements for each animal,
Fig. 3 a Optic nerves of mice 120 days after MOG or MBP immunization stained by H&E and CD3, Iba1, or MBP antibodies. Optic nerves were
compared by an established infiltration score according to H&E staining (b) (Shindler et al. [3]), MBP score for the myelin status (c), Iba1
fluorescence intensity measurement for microglia activation (d), and CD3+ cell infiltration (e). The bar graphs represent the pooled mean ±
standard deviation of at least two separate EAE experiments each with at least four animals per group; one optic nerve per mouse was included,
*P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant, by ANOVA with Dunnett’s post hoc test compared to sham-treated mice
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the sensitivity to detect treatment effects can be further
increased. As a functional measure, a sample size of 3
animals per group was determined to detect alteration of
the visual acuity of 15% at an effect strength of 3.7
(0.2286 c/d ± 0.011 c/d to 0.2686 c/d ± 0.011 c/d). For
histological staining of RGCs in retinal wholemounts
and the clinical EAE score at 120 days, the power ana-
lysis determined a sample size of 3 and 18 animals per
group, respectively, to detect a change as low as 25%
RGC survival and 50% EAE score at an effect strength of
4.45 (1181 RGCs/mm2 ± 200 RGCs to 1535 RGCs/
mm2 ± 200 RGCs) and 0.93 (2.26 EAE score ± 1.27 vs
1.19 EAE score ± 0.93), respectively.
In summary, based on the results of our previous
study, we can conclude that OCT and OKR in the
EAEON can detect protective treatment effects of 20
and 15% on retinal structure and visual function, re-
spectively, with reasonable sample sizes.
Fig. 4 a Electron microscopy images of longitudinal sections of the optic nerve fibers from sham- and MOG35–55-treated C57Bl/6J wild-type mice.
b The myelin-axon ratio was determined by the thickness of the myelin sheath and the axon. Bar graphs represent the pooled mean ± SD of an
EAE experiment with four animals per group; **P < 0.01 two-tailed Student’s t test compared to sham-treated mice
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Fig. 5 (See legend on next page.)
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Discussion
Retinal OCT is increasingly used as an outcome measure
for clinical trials of candidate neuroprotective drugs in
acute ON [23–26] and MS [27, 28]. Preclinical investiga-
tions in experimental ON using in vivo retinal outcomes
can be readily transferred to a clinical trial scenario, yet
the models best suited to address the different aspects
of retinal neurodegeneration by in vivo OCT are still
unknown. For this purpose, establishing the dynamics
of retinal neuroaxonal loss in EAE is also crucial.
Traditionally, EAE experiments mostly focus on clin-
ical and/or purely immunological aspects and extend
for 1 month. Our results indicate that in the MOG35–
55 EAE model in C57BL/6J mice, IRL thickness
changes during the course of the disease, reflecting
the clinical severity and RGC survival. Here, we ob-
served that slow retinal thinning after peak EAE con-
tinues until month 7 even though the clinical signs
remain stable. EAE scores almost exclusively represent
changes in motor function. This mirrors the current
situation in the clinic and in clinical trials, where dis-
ability is measured through the EDSS scale, which re-
lies heavily on the ambulatory capacity of patients.
Additionally, while EAE scores and EDSS are ordinal
scales and depend on the subjectivity of the scorer,
OCT provides an objective, continuous quantitative
anatomical readout.
We first analyzed the reproducibility and reliability of
retinal OCT measurements in mice. Altogether, volume
scans offered the best results, while the poorest were ob-
tained with the peripapillary ring scans which, in fact,
have been studied as an outcome parameter in animal
models of MS [29]. A possible explanation is that the
variability of the segmentation of single B-scans is aver-
aged out when analyzing the mean of the 49 scans mak-
ing up the volume scan. Our data indicate that in mice,
the separate assessment of the RNFL and GCIPL thick-
ness can be challenging, since the segmentation of the
limit between them is not very reproducible. We, there-
fore, also analyzed them jointly as the IRL, which yielded
much more robust results. Another advantage of evalu-
ating these layers together is that it reflects a combined
outcome parameter for axonal (RNFL) and neuronal
(GCIPL) loss.
We then investigated the extent and dynamics of ret-
inal injury in different mouse EAE models. The genetic
background of a mouse line, as well as the epitope used
for immunization, affects the immune and inflammatory
response during EAE. In Swiss-derived strains (e.g., SJL/
J), PLP immunization leads to a relapsing remitting
(See figure on previous page.)
Fig. 5 MOG35–55 EAE in C57Bl/6J (n = 17) vs. sham-immunized (n = 12) mice. a EAE clinical scores. b Decreased visual acuity of EAE mice
compared to untreated C57Bl/6J mice. OKR measurement was carried out for 120 days after MOG immunization as described above, area under
the curve compared by ANOVA with Dunnett’s post hoc test. c–f Thickness of retinal layers. h–l RGC count after 9 months. Data expressed as
mean ± SEM, *P < 0.05; **P < 0.01; ***P < 0.001. P values for OCT and RGC data obtained from generalized estimating equation models accounting
for within-mouse, inter-eye correlations. m–r Linear regression analyses. IRL thickness during EAE is associated with ultimate neuronal loss (top
row) and disease severity (bottom row). Similar results were obtained 5 and 7months after immunization (data not shown). ß, generalized
estimating equation association coefficient
Fig. 6 a Clinical EAE scores in PLP139–151 EAE in SJL mice. The abscissa axis represents days after immunization. b IRL thickness in PLP139–151 EAE
(n = 10) vs. sham-immunized (n = 5) SJL/J mice. Data expressed as mean ± SEM; *P < 0.05; **P < 0.01
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disease course, while mice with a Bl/6 background de-
velop a more chronic progression, thereby addressing
different forms of the inflammatory CNS disease [30].
Additionally, for neuroprotection studies, it may be par-
ticularly relevant to use models displaying severe retinal
damage to ensure that even small effect sizes of neuro-
protective interventions are detectable through OCT.
We, therefore, chose to also include the model of
PLP139–151-induced EAE in SJL/J mice and MOG35–55-
induced EAE in TCR2D2 mice as models with particu-
larly severe RGC degeneration [3] and ON, besides
MOG35–55-induced EAE in C57BL/6 WT mice [5]. Fur-
thermore, we aimed to investigate the retinal degener-
ation in MBP-induced EAE in C57Bl/6J mice as a model
characterized by a monophasic disease course and pre-
dominantly axonal damage but less demyelination [31].
In general, EAE induction in C57Bl/6J mice by MBP is
not very feasible [21, 22, 32]; nevertheless, we were able
to induce mild EAE signs with whole rat MBP, yet with
no significant retinal thinning or relevant pathology of
the optic nerve. Hence, we conclude that this model is
not suitable for retinal studies. EAE in SJL/J mice follow-
ing immunization against PLP139–151 could be used to
study retinal neurodegeneration in the context of re-
peated relapses. Even though OCT detected changes at-
tributable to EAE in the retinas of SJL/J mice, the
concomitant retinal dystrophy hinders further neuro-
physiological and histological investigations and signifi-
cantly limits the usefulness of this mouse strain for our
purposes. We, therefore, focused on mice with the
C57BL/6J background, obtaining results by the findings
of Knier et al. [9] and our own previous work [8, 33].
We sought to also characterize the changes in retinal
thickness during the acute phase of the disease. Serial
OCT 6, 15, 30, 60, 90, and 120 days after immunization
revealed three distinctive phases of retinal injury: no
changes in retinal thickness were detectable 6 days after
immunization (pre-EAE onset, data not shown); coincid-
ing with clinical onset and peak of disease, there was
considerable swelling of the IRL in WT mice, while ret-
inal degeneration in TCR2D2 mice stared already at this
early time point. The chronic phase of EAE was charac-
terized by progressive IRL thinning below baseline levels
both in WT and TCR2D2 mice. Histopathological exam-
ination revealed ON with T cell and microglial infiltrates
leading to RGC loss in the absence of clinical signs in
TCR2D2 mice injected only with PT, in line with the
observations of Guan et al. [17]. As IRL thickness is only
slightly decreased at day 30 compared to baseline, loss of
RGC might not be evident only 1 month after
immunization. Taken together, these analyses indicated
that in the MOG35–55 EAE model through direct
immunization of C57BL/6J mice, experiments using ret-
inal OCT as a surrogate for neuronal damage should last
more than 1month and use IRL thickness as their pri-
mary outcome.
We measured retinal thickness until changes relative
both to baseline levels and age-matched controls
stabilized, which happened around month 9 after
immunization. This continuation of IRL thinning far be-
yond the clinical stabilization of EAE suggests that OCT
might be more sensitive to assess the chronic neurode-
generation after an acute inflammatory insult. Although
significant IRL atrophy was already detectable after 1
month, these changes corresponded exclusively to the
GCIPL, and only from the second month were we able
also to detect thinning in the RNFL. By the end of the
experiment, however, relative thinning of the RNFL was
higher than that of the GCIPL. This aligns with studies
of ON in humans describing GCL thinning as an early
feature [34], detectable before that of the peripapillary
RNFL [35], but with ultimate macular RNFL atrophy be-
ing more extensive than that of the macular GCIPL [36].
The different timing of RNFL versus GCIPL atrophy has
been related to early edema of the RNFL during acute
ON or to RGC shrinkage and loss before axonal atrophy
occurs. According to this interpretation, RGC degener-
ation in ON would be driven by two related mecha-
nisms: an initial wave of RGC injury, caused by early
signals from damaged axons in the optic nerve, and a
later wave of RGC loss, as a consequence of a dying-
back process following axonal loss [36]. Our findings in
the animal laboratory seem to support these observa-
tions. Like in patients with ON [37], we saw changes in
the IRL thickness occurring most rapidly in the first
months after the acute episode.
Nine months after immunization, surviving RGC were
halved in MOG- versus sham-immunized mice. How-
ever, measuring IRL thickness longer than 2months did
not show to improve the association of IRL thickness
and RGC survival substantially. These results indicated
that MOG35–55 EAE studies using OCT as a surrogate
for the ultimate survival of RGC do not necessarily pro-
vide additional meaningful information beyond 2months
after direct immunization unless investigating mecha-
nisms of repair or specifically targeting processes that
occur in the late phase. Similarly, because in the MOG-
EAE model there is little clinical change beyond the
fourth week after immunization, IRL thickness measured
at 2 months was as good of a predictor of overall burden
of disease (cumulative EAE score) as that measured 1 or
9 months after immunization (r2 0.51, 0.47, and 0.52 at
1, 2, and 9months, respectively).
It should be noted that OCT is a method to image tis-
sue. It lacks real cellular resolution. Therefore, averaging
while enhancing reproducibility does not necessarily im-
prove fidelity. Each scan is the result of averaging 30 to
100 images, so the details of the interface between
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retinal layers might not be fully detected. We did not
compare the results with the retinal layer thickness mea-
surements to the layer thickness in histological sections
or assessments by other OCT devices or segmentation
algorithms. However, this was done in other studies [11,
38] and was not the focus of our work. As a result of
these limitations, measurements are obtained from an
idealized representation of the retina and can be influ-
enced by pathological changes that impact the optical
properties of the tissue under study.
The power analysis using our previously published re-
sults with alpha-lipoic acid [8] revealed that protective
effects of 20% on the retinal structure could be detected
with 14 animals per group, which is in line with other
studies using similar methodology [9, 39, 40]. Interest-
ingly, OKR analysis of visual function and RGC counting
in retinal wholemounts showed less variance resulting in
numbers as low as 3 animals per group in the power
analysis to detect 15% protection of visual function and
25% protection of RGCs. Of course, the power achieved
by the different modalities depends on the mode of ac-
tion of the therapeutic approaches studied.
Conclusions
IRL thickness, as assessed by retinal OCT, is a good sur-
rogate for clinical severity and neuronal loss and survival
in mouse models of EAE. During the onset and peak of
disease, there is acute IRL thickening, followed by pro-
gressive thinning. In MOG-EAE in C57BL/6J mice, this
occurs most rapidly between the height of disease and
the 60th day after immunization, and only from that
time point on is it possible to detect associated thinning
of the INL. In the otherwise healthy SJL/J adult mouse,
which is a homozygous carrier of the allele Pde6brd1,
there is progressive IRL thinning due to retinal dys-
trophy which is aggravated upon immunization with
PLP139–151. No significant retinal changes are found in
MBP-EAE in C57BL/6J mice. MOG immunization in
TCR2D2 mice results in severe EAE, therefore challen-
ging animal care and survival during experiments.
We conclude that among the models tested, MOG35–
55-induced EAE in C57Bl/6J is the most convenient to
study retinal neurodegeneration in the context of ON.
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